Alnylam Pharmaceuticals Announces Partial Repurchase of Convertible Senior Notes

Details

announced a partial repurchase of its 1.00% Convertible Senior Notes due 2027 for approximately $34.4 million in aggregate principal amount. The total repurchase cost, including accrued and unpaid interest, amounts to about $51.9 million. This repurchase is expected to close shortly after a measurement period, subject to customary closing conditions. Post-repurchase, approximately $362.8 million in aggregate principal amount of the Notes will remain outstanding. The announcement also confirmed that previously entered capped call transactions will remain unaffected by this repurchase.

Items reported

About Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.